Virology and Immunology of Hepatitis Viruses

  • Authors: Raymond T. Chung, MD; Esperance Anne Kreek Schaefer, MD, MPH (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 7/10/18 (What's New)

Summary

  • NAs have high rates of viral inhibition but carry risk of developing resistance
    • Rates vary across drug therapies with lamivudine having the highest rate of resistance
    • Resistance to entecavir develops at a much lower rate (1.2% after 5 years monotherapy), but it is significantly higher if there is already lamivudine resistance (51.0% after sequential monotherapy)

Action required